Abstract
Results: Unassisted AVF maturation failure without intervention occurred in 54.0% of participants, and overall AVF maturation failure (with or without intervention) occurred in 30.1%. After covariate adjustment, CCB use was associated with a 25% lower risk of overall AVF maturation failure (95% CI 3%-41% lower) but a non-significant 10% lower risk of unassisted maturation failure (95% CI 23% lower to 5% higher). ACE-I/ARB, beta-blocker, and diuretic use was not significantly associated with AVF maturation outcomes. None of the antihypertensive medication classes were associated with changes in AVF diameter or blood flow over 6 weeks following surgery. Conclusions: CCB use may be associated with a lower risk of overall AVF maturation failure. Further studies are needed to determine whether CCBs might play a causal role in improving AVF maturation outcomes.
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Background
Hemodialysis is the most common form of renal replacement therapy in the United States with more than 100,000 Americans initiating maintenance hemodialysis each year [1] . The arteriovenous fistula (AVF) is the preferred method of vascular access due to greater longevity, lower infection rates, and longer survival compared to other access methods [2] . However, approximately onehalf of surgically created AVFs fail to mature and no therapies can meaningfully improve AVF maturation outcomes [3] . Identifying modifiable risk factors for AVF maturation failure is an important step toward suggesting new therapeutic interventions.
Angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCB) are commonly prescribed to hemodialysis patients and may promote AVF maturation through diverse mechanisms. Angiotensin II induces growth factor production and stimulates vascular smooth muscle cell proliferation [4, 5] . In vitro and animal experimental models of vascular injury have demonstrated that angiotensin blockade halts vascular smooth cell migration and reduces endothelial intimal formation [6] [7] [8] [9] . CCBs reduce cellular calcium entry, which mitigates pathologic intracellular calcium overload of end-stage renal disease, increases stable nitric oxide metabolites, and prevents apoptosis [10, 11] . Previous studies have reported associations of ACE-I/ARBs and CCBs with greater patency of existing AVFs and arteriovenous grafts (AVGs), but few have investigated associations with primary AVF maturation [12] [13] [14] [15] .
We hypothesized that ACE-I/ARB and CCB use would be associated with lower rates of AVF maturation failure. To test this hypothesis, we evaluated associations of ACE-I/ARB and CCB use, at baseline, with clinical AVF outcomes of overall and unassisted maturation in the prospective Hemodialysis Fistula Maturation (HFM) Study. In exploratory analyses, we also assessed the associations of beta-blockers and diuretics, 2 other commonly prescribed anti-hypertensive medication classes, with clinical maturation outcomes.
Methods
Study Population
The HFM Study enrolled 602 participants, each undergoing the creation of a single autogenous upper extremity AVF between 2010 and 2013 at 1 of 7 study sites in the United States [16] . Study participants were either receiving maintenance dialysis or expected to start dialysis within 3 months of planned AVF surgery. Exclusion criteria were age less than 18 years or greater than 80 years if not yet on dialysis, inability to provide informed consent, and life expectancy less than 9 months. All participants gave written informed consent and Institutional Review Board approval was obtained at each study site.
Ascertainment of Antihypertensive Medication Use
HFM Study personnel obtained names of all active medications from participants by interview and chart review within 45 days prior to planned AVF surgery. Specific medication dosages and administration schedules were not collected. Moreover, information regarding intravenous medications provided during dialysis was not abstracted. All medications were coded using the World Health Organization drug system. We classified antihypertensive medications into 1 of 4 mutually exclusive categories: (1) angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), (2) beta-blockers, (3) calcium channel blockers (CCBs), and (4) diuretics. For additional analyses, we further sub-classified ACE-I/ARB separately as ACE-I and ARB, and CCB as dihydropyridine (DHP) and non-DHP.
Determination of AVF Maturation Outcomes
We evaluated the HFM Study outcomes of unassisted and overall AVF maturation [16] . Unassisted AVF maturation, which is the primary HFM Study outcome, was defined as successful clinical use of the AVF for hemodialysis within 9 months of surgical placement, or within 4 weeks of initiating hemodialysis without maturation-enhancing procedures. Successful clinical use entailed the use of the AVF with 2 needles for at least 75% of hemodialysis sessions during a 4-week period plus either (1) a mean dialysis blood pump speed greater ≥300 mL/min for 4 consecutive sessions, or (2) a measured spKt/V ≥1.4 or URR > 70% in any session during the 4 week period, with the above time windows applied to the first of the 4 days that a mean pump speed ≥300 mL/min, or the first day an spKt/V ≥1.4 or URR > 70% is achieved. Overall AVF maturation was identified using the same criteria, but allowing additional ancillary procedures to promote AVF maturation if needed.
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Preoperative and Postoperative Ultrasound Measurements Centrally trained study sonographers at each clinical site performed preoperative (baseline) ultrasound mapping of arteries and veins in the arm intended for AVF creation. Sonographers obtained subsequent ultrasound images of the surgically created AVF early postoperatively (days 0-3, targeting day 1), and at weeks 2 and 6. All ultrasound measurements were obtained following a standardized HFM protocol that has been previously described [17] . Measurements and imaging data were transmitted to the HFM Ultrasound Core, where a sonographer blinded to the study data evaluated images and measurements for accuracy and adherence to protocol. HFM Study radiologists, also blinded to the study data, then read the images and entered the results into the study database.
Other Study Variables HFM Study personnel used patient interviews and medical records to complete standardized forms recording patient demographics, medical histories, dialysis and vascular access histories, and social habits. Such information was updated if more than 45 days elapsed before AVF surgery. Participant demographics and lifestyle factors included age, sex, race, smoking status, and highest education level completed. Comorbid conditions included histories of coronary artery disease (angina, myocardial infarction, coronary artery bypass, or percutaneous coronary revascularization), congestive heart failure (New York Heart Association Class II or greater), and diabetes. HFM Study personnel also collected height, weight, and 3 resting blood pressures in the non-access arm.
Statistical Analysis
We tabulated baseline characteristics of HFM Study participants by the use versus non-use of each anti-hypertensive medication class. We calculated the unassisted and overall AVF maturation failure proportions for users and non-users and used Poisson regression with robust standard errors to estimate the relative risk (RR) of AVF maturation failure associated with use of each antihypertensive medication class. We formulated 3 covariate adjustment models prior to analyses. The first model adjusted for age, sex, race (black versus non-black), and study site. The second model added adjustments for body mass index, history of diabetes and congestive heart failure, dialysis status, AVF location, smoking status, and highest level of education. A third model, viewed as primary, added adjustments for baseline systolic blood pressure and the remaining antihypertensive medication classes to estimate independent associations for each class. We also tested the 2-, 3-, and 4-way interactions among the 4 medication classes with a single omnibus test. We conducted additional analyses to assess separate associations for ACE-Is and ARBs, and for DHP and non-DHP CCBs. For these sensitivity analyses only, we excluded participants who were concomitantly on ACE-Is and ARBs (n = 14) or DHP and non-DHP CCBs (n = 2).
We ascertained ultrasound measurements of AVF flow (mL/ min) and draining vein diameter (mm) for each patient during a pre-operative vessel mapping examination, early postoperatively (days 0-3, targeting day 1), week 2, and week 6. We constructed linear mixed models to examine the differences in temporal changes in ultrasound measurement between users and non-users of each antihypertensive class. In each case, the linear mixed model allowed for a random effect of the patient, main effects of time modeled continuously and the antihypertensive class of interest, the interaction between these 2, and additional covariates as described earlier. Statistical significance of the linear interaction between the time and use of the antihypertensive class of interest was taken to be evidence of a difference in the change in AVF diameter or flow between users and non-users.
For all regression analyses, we used multiple imputations with 10 imputations and chained equations to account for missingness in covariates and AVF outcomes [18, 19] . We combined the resulting estimates using Rubin's rules to account for variability in the imputation procedure [20] . A 2-sided p value of 0.05 was considered significant for all analyses. Analyses were conducted using open-source package R version 3.3.0 (R Foundation, Vienna, Austria) [21] and STATA 11 (College Station, TX, USA) [22] . We used the lmer function in the lme4 R package [23] for linear mixed models and the glm function in R for Poisson regression models.
Results
Description of the Study Population
Among the 602-person HFM Study cohort, the mean age was 55.1 years; 423 participants (70.2%) were male, 264 (43.8%) were black, and 383 (63.6%) were receiving maintenance dialysis at the time of surgery. Anti-hypertensive medication use was highly prevalent in the HFM Study cohort, with respectively 70 (11.6%), 135 (22.4%), and 365 (60.6%) participants reporting use of 1, 3, and 3-4 anti-hypertensive medication classes. The most commonly used anti-hypertensive medication classes were beta-blockers (73.0%), followed by CCBs (65.2%), diuretics (48.5%), and ACE-I/ARBs (47.1%). Baseline characteristics of ACE-I/ARB and CCB users were generally similar to those of non-users of these medications (Table 1). CCB users were more likely to be black (46.6 vs. 38.8%) and less likely to be receiving maintenance hemodialysis (59.0 vs. 72.2%) compared to non-CCB users. Diuretic and beta-blocker users tended to have more comorbid conditions compared to non-users (online suppl. Tables 1-2 ; for all online suppl. material, see www.karger. com/doi/10.1159/000491828). Users of each antihypertensive class tended to have higher baseline systolic blood pressures compared to non-users (Table 1; online suppl.  Tables 1, 2) .
Associations with Unassisted AVF Maturation Failure
In the multiply-imputed data, failure to achieve unassisted AVF maturation occurred in an average of 325 HFM Study participants (54.0%). None of the drug classes showed statistically significant association with unassisted maturation failure under any adjustment model (Table 2 ). More specifically, ACE-I/ARB users had a higher crude incidence of unassisted AVF matura- 
Associations with Overall AVF Maturation Failure
Two hundred and thirteen (35.4%) HFM participants required at least one intervention to promote maturation after AVF creation. Angioplasty was the most common intervention (26.1%), followed by occlusion of accessory vein (6.1%), fistula repositioning (4.2%), and thrombectomy (3.0%). Failure to achieve the overall AVF maturation occurred in an average of 181 HFM Study participants (30.1%). Users and non-users of ACE-I/ARB and beta-blocker demonstrated similar unadjusted incidences of overall AVF maturation failure (Table 3) . CCB use was associated with a statistically significant 23-25% low- er risk of overall maturation failure after full covariate adjustment in Models 2 and 3 (95% CI 3%-41% lower; p = 0.03, after Model 3 adjustment). Diuretic use was associated with a nonsignificant 20-29% greater risk of overall maturation failure across all levels of adjustment. The association of CCB use with lower rates of overall AVF maturation failure was not statistically and significantly modified by use versus non-use of ACE-I/ARB, beta-blockers, or diuretics ( Fig. 1; omnibus p- 
Association with Postoperative AVF Diameter and Flow
Venous diameter and blood flow increased substantially within one day following AVF creation surgery, followed by smaller increases after 2 and 6 weeks. Diameter and flow were substantially greater in upper arm AVFs compared to forearm AVFs (online suppl. Fig. 1 ) [17] . There were no significant differences in changes in vein diameter (p = 0.12) or AVF flow (p = 0.96) over time between ACE-I/ARB users and non-users (online suppl. Fig. 1 ), CCB users and non-users (diameter p = 0.63, blood flow p = 0.35; online suppl. Fig. 2 ), or between users and non-users of beta-blockers (online suppl. Fig. 3 ) and diuretics (online suppl. Fig. 4) .
Discussion
In summary, we observed an association of CCB use within 45 days of AVF creation surgery with a lower incidence of overall AVF maturation failure in a prospective cohort study of 602 patients undergoing AVF creation surgery. CCB use was also associated with a numerically lower, but not statistically significantly different, incidence of unassisted AVF maturation failure. In contrast, the use of ACE-I/ARBs and other anti-hypertensive medication classes were not associated with unassisted or overall AVF maturation failure.
To our knowledge, this is only the second study to assess anti-hypertensive medication use in relation to primary AVF maturation. A previous single-center study of 97 AVFs also observed a higher rate of AVF maturation among CCB users (84%) compared to non-users (46%) [15] . Most previous studies have evaluated ACE-Is and CCBs in relation to the maintenance of AVF and AVG patency. For example, a retrospective cohort study of hemodialysis patients undergoing angioplasty for access stenosis reported CCB use to be associated with a 32% higher patency rate for AVFs and 25% higher patency rate for AVGs [12] . The Dialysis Outcomes and Practice Patterns study, which evaluated 900 hemodialysis patients with AVFs and 1,944 patients with AVGs, observed associations of CCB use with higher rates of primary AVG patency and ACE-I use with improved secondary AVF patency [13] . Moreover, Chen et al. [14] reported lower risks of AVF and AVG failure associated with ACE-I/ ARB and CCB use in a study of 37,771 AVFs and 4,473 AVGs. These observational data suggest that ACE-I and CCBs may enhance the lifespan of existing vascular accesses, but do not address possible effects on primary AVF maturation.
Several factors have been suggested to influence AVF maturation. The innate ability of the artery to dilate, as reflected by both flow-and nitroglycerin-mediated dilation, was associated with AVF development on ultrasonography in a prior HFM study [19] . CCBs may promote vasodilation of the arterialized vein post AVF creation. However, we were unable to detect differences in postsurgical trajectories of AVF diameter or flow, assessed by ultrasonography, comparing CCB users to non-users in the present study. CCBs may also inhibit endothelial neointimal hyperplasia through the inhibition of calcium influx via L-type calcium channels, a critical process for vascular smooth muscle cell growth and migration [24] . In-vitro models of coronary atherosclerosis have demonstrated dose-dependent inhibitory actions of CCBs on smooth muscle cell proliferation [25, 26] . In animal models of vascular injury, the administration of CCB decreased aortic neointimal area [27, 28] . In a human trial of patients with concomitant hypertension, diabetes, and coronary artery disease, CCBs reduced the progression of carotid neointimal area more than diuretics, beta-blockers, or ACE-I despite comparable blood pressure reductions [29] . CCBs may also decrease intracellular calcium signaling by inhibiting calcium release from the sarcoplasmic reticulum [30, 31] . However, the role of neointimal hyperplasia in AVF maturation is uncertain. Several studies, including the HFM Study, have not established a significant association of preexisting venous hyperplasia with clinical AVF maturation failure [32] [33] [34] . On the other hand, postoperative venous stenosis on ultrasound was associated with both unassisted and overall AVF maturation failure [34] . To the extent that AVF maturation may be attributed to neointimal hyperplasia and stenosis, it is plausible that CCB promotes AVF maturation by inhibiting hyperplasia that develops after the creation of the AVF.
We observed a non-statistically significant trend toward lower rates of overall AVF maturation failure associated with non-DHP versus DHP CCBs. In experimental models, verapamil and diltiazem have been shown to be more potent inhibitors of vascular smooth muscle cell functions compared to nifedipine [35] . Verapamil has also been shown to be a potent inhibitor of platelet aggregation and promoter of endothelial-dependent relaxation of coronary artery bypass graft [36, 37] . Observational studies have demonstrated that that CCBs confer mortality benefit in dialysis patients, and a retrospective study suggested lower all-cause and cardiovascular mortality in users of DHP compared to non-DHP [38] [39] [40] [41] [42] . DHP and non-DHP CCBs differ in their peripheral and central physiologic effects. DHP CCBs share a common chemical structure derived from pyridine and have known vascular dilatory properties. In comparison, non-DHP CCBs exert more negative chronotropic effects [43] . While DHP CCBs are recommended agents for hypertension treatment in dialysis patients [44] , we advise cautious interpretation of our findings and do not suggest selective prescription of CCBs for the purpose of fistula maturation.
The primary limitation of this study is the potential for confounding-by-indication. It is possible that unmeasured characteristics of CCB users versus non-CCB users distorted the observed association with overall AVF maturation failure. The possibility of confounding is moderated to some degree by concurrent evaluation of other anti-hypertensive medication classes, which may be prescribed for similar indications, and by adjustment for known predictors of AVF maturation that were measured using standardized procedures. A second limitation is the possibility of false discovery in the context of multiple testing. CCB use was associated with significant differences in overall AVF maturation failure but not with unassisted maturation failure, in the context of testing 4 medication classes, 2 AVF maturation outcomes, and across multiple adjustment models. Failure to reach statistical significance for unassisted AVF maturation failure may have been due to inadequate study power. However, the possibility of false discovery requires a cautious interpretation and replication of these findings in other studies. Combination effects from the simultaneous use of several antihypertensive classes may have also influenced our results. We have addressed this overlap by adjusting for use of other medication classes in our analyses, although we recognize that we are not powered to conduct individual sub-group analyses. Finally, the HFM Study assessed the use versus non-use of medications of interest at a single time point, precluding assessment of dosage or duration of therapy. A causal benefit of CCB also cannot be inferred based on our results.
An important strength of this study is the evaluation of primary AVF maturation outcomes within the largest prospective study of AVF maturation conducted to date. The multi-center setting of the HFM Study enhances the applicability of our findings beyond the practice patterns of a single clinical site. A second strength is the examination of several anti-hypertensive medication classes in association with AVF outcomes.
Conclusions
CCB use was associated with a lower risk of overall clinical AVF maturation failure. Further studies are needed to probe potential relevant mechanisms of action. Ultimately, randomized clinical trials are necessary to determine whether CCBs play a causal role in promoting AVF maturation.
